Itamar Medical wins China marketing approval

"Entry into the Chinese medical devices market is an opportunity, given the market's size."

Itamar Medical Ltd. (TASE:ITMR) has obtained marketing approval from China's State Food and Drug Association (SFDA) for its EndoPat and WatchPat non-invasive monitoring devices for monitoring sleep disorders and cardiovascular activity, respectively. The company is readying for sales of the devices in China.

The company said that entry into the Chinese medical devices market is an opportunity, given the market's size.

The European Medicines Agency (EMEA) and US Food and Drug Administration (FDA) have already approved both the EndoPat and WatchPat.

Itamar Medical's share price rose 6.6% by mid-afternoon to NIS 2.10, giving a market cap of NIS 263 million.

Published by Globes [online], Israel business news - - on March 27, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס Capital  Markets Conference 2017